Fig. 1From: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching studyMaximum Change from Baseline in the Sum of Longest Diameters. Anti-PD-1 plus sorafenib demonstrated more tumor shrinkage and disease control. PD was defined as 20% increase in tumor size, while partial response had a 30% decrease. (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease)Back to article page